公开(公告)号：US08889683B2

公开(公告)日：2014-11-18

申请号：US13242426

申请日：2011-09-23

Applicant: Clifford Cheng ,  Gerald W. Shipps, Jr. ,  Xiaohua Huang ,  Ying Huang ,  Ning Shao ,  Ashwin Rao ,  Anandan Palani ,  Peter Orth ,  Johannes H. Voigt ,  Robert J. Herr ,  Lana Michele Rossiter ,  Qi Zeng ,  Xianfeng Sun

Inventor： Clifford Cheng ,  Gerald W. Shipps, Jr. ,  Xiaohua Huang ,  Ying Huang ,  Ning Shao ,  Ashwin Rao ,  Anandan Palani ,  Peter Orth ,  Johannes H. Voigt ,  Robert J. Herr ,  Lana Michele Rossiter ,  Qi Zeng ,  Xianfeng Sun

IPC: A61K31/498 ,  C07D241/44 ,  C07D401/14 ,  C07D403/14 ,  C07D413/06 ,  C07D401/06 ,  C07D403/12 ,  C07D403/06

CPC classification number: C07D403/06 ,  C07D241/44 ,  C07D401/06 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/06

Abstract: The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Abstract translation: 本发明涉及式I的新型喹喔啉化合物：作为脂肪酸结合蛋白（“FABP”）抑制剂，包含喹喔啉化合物的药物组合物和喹喔啉化合物用于治疗或预防心血管疾病，代谢紊乱，肥胖症 或肥胖相关疾病，糖尿病，血脂异常，糖尿病并发症，葡萄糖耐量降低或空腹血糖受损。

公开(公告)号：US20120122837A1

公开(公告)日：2012-05-17

申请号：US13242426

申请日：2011-09-23

Applicant: CLIFFORD CHENG ,  GERALD W. SHIPPS, JR. ,  XIAOHUA HUANG ,  YING HUANG ,  NING SHAO ,  ASHWIN RAO ,  ANANDAN PALANI ,  PETER ORTH ,  JOHANNES H. VOIGT ,  ROBERT J. HERR ,  LANA MICHELE ROSSITER ,  QI ZENG ,  XIANFENG SUN

Inventor： CLIFFORD CHENG ,  GERALD W. SHIPPS, JR. ,  XIAOHUA HUANG ,  YING HUANG ,  NING SHAO ,  ASHWIN RAO ,  ANANDAN PALANI ,  PETER ORTH ,  JOHANNES H. VOIGT ,  ROBERT J. HERR ,  LANA MICHELE ROSSITER ,  QI ZENG ,  XIANFENG SUN

IPC: A61K31/498 ,  A61K31/5377 ,  A61K31/4709 ,  C07D413/06 ,  A61K31/506 ,  C07D471/04 ,  C07D403/06 ,  C07D401/14 ,  A61K31/4985 ,  C07D403/14 ,  C07D241/44 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P3/06 ,  A61K31/55

CPC classification number: C07D403/06 ,  C07D241/44 ,  C07D401/06 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/06

Abstract: The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Abstract translation: 本发明涉及作为脂肪酸结合蛋白（“FABP”）抑制剂的新型杂环化合物，包含杂环化合物的药物组合物和用于治疗或预防心血管疾病，代谢障碍，肥胖或肥胖相关的化合物的用途 糖尿病，血脂异常，糖尿病并发症，葡萄糖耐量减低或空腹血糖受损。

公开(公告)号：US6004660A

公开(公告)日：1999-12-21

申请号：US41321

申请日：1998-03-12

Applicant: Alvin Stanley Topolski ,  Clifford Cheng-Shiou Chang ,  George Merton Gordon Cumberbatch ,  David Henry Britt

Inventor： Alvin Stanley Topolski ,  Clifford Cheng-Shiou Chang ,  George Merton Gordon Cumberbatch ,  David Henry Britt

IPC: B32B15/08 ,  B32B27/36 ,  C08J7/04 ,  C23C14/20 ,  B32B7/02

CPC classification number: C08J7/045 ,  B32B27/36 ,  Y10T428/24802 ,  Y10T428/24942 ,  Y10T428/31678

Abstract: A composite film structure containing two inorganic layers each being not greater than 600 angstroms in thickness and having an oxygen transmission rate (OTR) not greater than 0.8 cubic centimeters/square meter-day-atmosphere with one of the layers in contact or in substantial contact with a polymeric barrier layer having an oxygen permeability coefficient (OPV) not greater than 1.5 cubic centimeters-25 microns/square meter-day-atm. The composite film structure has an oxygen transmission rate (OTR) of not greater than 0.012 cubic centimeters/square meter-day-atm and can be used in vacuum panel insulation structures.

Abstract translation: 含有两个无机层的复合膜结构的厚度不大于600埃，氧传输速率（OTR）不大于0.8立方厘米/平方米 - 天气氛，其中一层接触或基本接触 其具有不大于1.5立方厘米-25微米/平方米天的氧气渗透系数（OPV）的聚合物阻挡层。 复合膜结构的氧气透过率（OTR）不大于0.012立方厘米/平方米 - 天 - 可用于真空面板绝缘结构。

公开(公告)号：US06114021A

公开(公告)日：2000-09-05

申请号：US683548

申请日：1996-07-16

Applicant: Richard Paul Pankratz ,  Clifford Cheng-Shiou Chang ,  Marc Bandman

Inventor： Richard Paul Pankratz ,  Clifford Cheng-Shiou Chang ,  Marc Bandman

IPC: C09D5/00 ,  B32B27/36 ,  C08J7/00 ,  C08J7/04 ,  C09D123/08 ,  C09D161/32 ,  C09D163/00 ,  C09D175/00 ,  C09D179/00 ,  B32B15/08

CPC classification number: C08J7/045 ,  C08J7/04 ,  C09D123/08 ,  C08J2323/02 ,  C08J2367/02 ,  C08J2377/00 ,  Y10S428/91 ,  Y10T428/24959 ,  Y10T428/31565 ,  Y10T428/31692 ,  Y10T428/31797 ,  Y10T428/31855 ,  Y10T428/31909

Abstract: This invention covers a film base wherein polymers forming a polymeric film surface and selected from polyesters, polyolefins and polyamides are coated with an adhesion enhancing primer coating containing (a) a functionalized .alpha.-olefin containing copolymer; and (b) a crosslinking agent selected from the group consisting of amino formaldehyde resins, polyvalent metal salts, isocyanates, blocked isocyanates, epoxy resins and polyfunctional aziridines; and wherein the adhesion enhancing primer coating is applied to the polymeric film surface and reacted, at elevated temperatures with newly generated polymeric film surfaces formed during uniaxial or biaxial stretching and heat setting.

Abstract translation: 本发明涉及一种薄膜基底，其中形成聚合物薄膜表面并选自聚酯，聚烯烃和聚酰胺的聚合物用粘合增强底漆涂层包含（a）官能化含α-烯烃共聚物; 和（b）选自氨基甲醛树脂，多价金属盐，异氰酸酯，封端异氰酸酯，环氧树脂和多官能氮丙啶的交联剂; 并且其中将粘合增强底漆涂层施加到聚合物膜表面，并在升高的温度下与在单轴或双轴拉伸和热定型期间形成的新生成的聚合物膜表面反应。